XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.20.2

Investment In Joint Ventures And Minority Interests | 9 Months Ended
--- | ---
Sep. 30, 2020
Equity Method Investments And Joint Ventures [Abstract] |
Investment In Joint Ventures And Minority Interests |
7 | INVESTMENT IN JOINT VENTURES AND MINORITY INTERESTS
Summarized Equity Earnings (Losses) from Unconsolidated Entities
|  | Three months ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Pure Sunfarms |  | $ | 1,443 |  |  | $ | 3,748 |  |  | $ | 5,437 |  |  | $ | 14,493 |
VF Hemp |  |  | (137 | ) |  |  | (211 | ) |  |  | (552 | ) |  |  | (343 | )
AVGG Hemp |  |  | — |  |  |  | (18 | ) |  |  | — |  |  |  | (35 | )
Total |  | $ | 1,306 |  |  | $ | 3,519 |  |  | $ | 4,885 |  |  | $ | 14,115 |
Pure Sunfarms Corp. On June 6, 2017, the Company entered into an agreement to form Pure Sunfarms, a B.C. corporation, with Emerald Health Therapeutics Inc. (“Emerald”). The purpose of Pure Sunfarms is to produce, market and distribute cannabis in Canada and internationally. The Company accounts for its investment in Pure Sunfarms, in accordance with ASC 323, Equity Method and Joint Ventures (“ASC 323”), using the equity method. The Company has determined that Pure Sunfarms is a variable interest entity (“VIE”), however the Company does not consolidate Pure Sunfarms because the Company is not the primary beneficiary. Although the Company is able to exercise significant influence over the operating and financial policies of Pure Sunfarms through its 58.7% majority interest, the Company shares joint control of the Board of Directors and therefore is not the primary beneficiary. The Company’s maximum exposure to loss as a result of its involvement with Pure Sunfarms as of September 30, 2020 relates primarily to the Company’s investment of $63,164 and the recovery of the outstanding loan to Pure Sunfarms of $10,954. The Company is required to apply the hypothetical liquidation at book value (“HLBV”) method to determine its allocation of the profits and losses in Pure Sunfarms. When determining its allocation of profits and losses, the HLBV method only considers shares that have been fully paid for. Therefore, due to the monthly escrow payments made by Emerald in 2019 in accordance with the Delta 2 Option and Escrow Agreements, the ownership changed each month in 2019 as escrow payment(s) were made. Under the hypothetical liquidation method, the Company received 58.7% and 56.1% of Pure Sunfarms’ earnings for the three months ended September 30, 2020 and 2019, respectively. For the nine months ended September 30, 2020 and 2019, the Company received 57.8% and 60.1% of Pure Sunfarms’ earnings, respectively. On March 31, 2019, Pure Sunfarms exercised its option to utilize the Delta 2 assets and operations. The contribution of the assets has been accounted for as a disposal of the land, greenhouse facility and other assets in exchange for 25,000,000 common shares of Pure Sunfarms. This was a non-cash transaction, and it was estimated that the fair value of the land, building and other assets was $18.7 million (CA$25.0 million) at the date of contribution. The Company recognized a gain of $13.6 million on the contribution of the fixed assets. On March 2, 2020, pursuant to the settlement agreement with Emerald (the “Settlement Agreement”), Emerald transferred to the Company 2.5% of additional equity in Pure Sunfarms. The Company determined the fair value of the equity received from Emerald to be $4.7 million (CA$6.5 million). The Company recorded this amount as a gain on settlement agreement in the Condensed Consolidated Interim Statement of Income (Loss) and Comprehensive Income (Loss) for the nine months ended September 30, 2020. As of September 30, 2020, and December 31, 2019, the total investment in Pure Sunfarms of $63.2 million and $41.3 million, respectively, was recorded in the consolidated statements of financial position. The Company’s share of the joint venture consisted of the following:
Balance, January 1, 2019 |  | $ | 6,341 |
Investments in joint venture |  |  | 18,717 |
Share of net income for the year |  |  | 16,276 |
Balance, December 31, 2019 |  | $ | 41,334 |
Balance, January 1, 2020 |  | $ | 41,334 |
Investments in joint venture |  |  | 16,393 |
Share of net income for the period |  |  | 5,437 |
Balance, September 30, 2020 |  | $ | 63,164 |
Summarized financial information of Pure Sunfarms:
|  | September 30, 2020 |  |  | December 31, 2019 |
Current assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 6,751 |  |  | $ | 7,356 |
Trade receivables |  |  | 13,543 |  |  |  | 8,687 |
Inventory |  |  | 33,676 |  |  |  | 21,745 |
Other current assets |  |  | 5,759 |  |  |  | 6,964 |
Non-current assets |  |  | 115,720 |  |  |  | 108,652 |
Current liabilities |  |  |  |  |  |  |  |
Trade payables |  |  | (3,422 | ) |  |  | (4,938 | )
Borrowings due to joint ventures |  |  | (11,022 | ) |  |  | (26,413 | )
Income taxes payable |  |  | — |  |  |  | (8,489 | )
Borrowings – current |  |  | (2,291 | ) |  |  | (1,423 | )
Other current liabilities |  |  | (10,156 | ) |  |  | (5,021 | )
Non-current liabilities |  |  |  |  |  |  |  |
Borrowings – long term |  |  | (23,709 | ) |  |  | (13,089 | )
Deferred tax liabilities |  |  | (13,742 | ) |  |  | (2,473 | )
Net assets |  | $ | 111,107 |  |  | $ | 91,558 |
Reconciliation of net assets: |  |  |  |  |  |  |  |
Accumulated retained earnings |  | $ | 36,091 |  |  | $ | 26,679 |
Contributions from joint venture partners |  |  | 75,738 |  |  |  | 63,481 |
Currency translation adjustment |  |  | (722 | ) |  |  | 1,398 |
Net assets |  | $ | 111,107 |  |  |  | 91,558 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Sales |  | $ | 17,048 |  |  | $ | 18,084 |  |  | $ | 39,571 |  |  | $ | 53,128 |
Cost of sales* |  |  | (11,154 | ) |  |  | (5,689 | ) |  |  | (23,678 | ) |  |  | (13,463 | )
Gross Margin |  |  | 5,894 |  |  |  | 12,395 |  |  |  | 15,893 |  |  |  | 39,665 |
Selling, general and administrative expenses |  |  | (2,447 | ) |  |  | (2,830 | ) |  |  | (6,731 | ) |  |  | (5,616 | )
Income from operations |  |  | 3,447 |  |  |  | 9,565 |  |  |  | 9,162 |  |  |  | 34,049 |
Interest expense |  |  | (386 | ) |  |  | (302 | ) |  |  | (734 | ) |  |  | (596 | )
Foreign exchange (loss) gain |  |  | (56 | ) |  |  | 14 |  |  |  | (207 | ) |  |  | 28 |
Other income, net** |  |  | (131 | ) |  |  | 8 |  |  |  | 4,202 |  |  |  | 22 |
Income before taxes |  |  | 2,874 |  |  |  | 9,285 |  |  |  | 12,423 |  |  |  | 33,503 |
Provision for income taxes |  |  | (417 | ) |  |  | (2,600 | ) |  |  | (3,012 | ) |  |  | (9,397 | )
Net Income |  | $ | 2,457 |  |  | $ | 6,685 |  |  | $ | 9,411 |  |  | $ | 24,106 |
| * | Included in cost of sales for the three months ended September 30, 2020 and 2019 is $961 and $503, and nine months ended September 30, 2020 and 2019 is $1,973 and $1,347 respectively, of depreciation expense.
| ** | Nine months ended September 30, 2020, includes a gain recognized on the settlement of net liabilities of $4,348.
Village Fields Hemp USA LLC On February 27, 2019, the Company entered into a joint venture with Nature Crisp, LLC (“Nature Crisp”) to form VF Hemp for the objective of outdoor cultivation of high percentage cannabidiol (“CBD”) hemp and CBD extraction in multiple states throughout the United States. VF Hemp is 65% owned by the Company and 35% owned by Nature Crisp. Under the terms of the VF Hemp Joint Venture Agreement, the Company will lend up to approximately $15 million to VF Hemp for start-up costs and working capital. The Company accounts for its investment in VF Hemp, in accordance with ASC 323, using the equity method because the Company is able to exercise significant influence over the operating and financial policies of VF Hemp through its 65% ownership interest and joint power arrangement with Nature Crisp. The Company’s maximum exposure to loss as a result of its involvement with VF Hemp is directly related to the recovery of the $10,713 loan outstanding to VF Hemp. The Company’s share of the joint venture consisted of the following:
Balance, January 1, 2019 |  | $ | — |
Investments in joint venture |  |  | 7 |
Share of net loss |  |  | (2,464 | )
Losses applied against joint venture note receivable |  |  | 2,457 |
Balance, December 31, 2019 |  | $ | — |
Balance, January 1, 2020 |  | $ | — |
Investments in joint venture |  |  | — |
Share of net loss |  |  | (552 | )
Losses applied against joint venture note receivable |  |  | 552 |
Balance, September 30, 2020 |  | $ | — |
Summarized financial information of VF Hemp:
|  | September 30, 2020 |  |  | December 31, 2019 |
Current assets |  |  |  |  |  |  |  |
Inventory |  | $ | 9,268 |  |  | $ | 9,308 |
Other current assets |  |  | 242 |  |  |  | 546 |
Non-current assets |  |  | 989 |  |  |  | 1,476 |
Current liabilities |  |  | (1,433 | ) |  |  | (1,788 | )
Non-current liabilities |  |  | (13,697 | ) |  |  | (13,323 | )
Net assets |  | $ | (4,631 | ) |  | $ | (3,781 | )
Reconciliation of net assets: |  |  |  |  |  |  |  |
Accumulated retained earnings |  | $ | (3,791 | ) |  | $ | (3,791 | )
Net loss for the nine months ended September 30, 2020 |  |  | (850 | ) |  |  | — |
Contributions from joint venture partners |  |  | 10 |  |  |  | 10 |
Net assets |  | $ | (4,631 | ) |  | $ | (3,781 | )
In July 2020, the Company invested $226, for an approximately 16% minority interest ownership in DutchCanGrow Inc. (“DCG”), a Netherlands-based cannabis enterprise. DCG is pursuing the opportunity to become one of a limited number of licensed cannabis growers (up to a maximum of 10) when the Dutch government permits the first legal recreational cannabis market in Europe under its 10-city Experiment to Investigate Closed Cannabis Supply Chains. In August 2020, the Company invested $1,000 for a 6.6% minority interest ownership in Australia-based Altum International Pty Ltd (“Altum”), with an option to increase its ownership in Altum on similar terms. Altum is a cannabinoid platform with a focus on the distribution and marketing of CBD products in the Asia-Pacific region.

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -URI http://asc.fasb.org/topic&trid=2196965 + Details
Name: | us-gaap_EquityMethodInvestmentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration